Swiss drug company Roche Holding AG and GlaxoSmithKlin, have been granted U.S. approval for long-lasting intravenous use of their osteoporosis drug Boniva, (Bonviva in Europe).
The drug is used in post-menopausal women and allows patients to receive an injection just once every three months.